Galmed's Aramchol Gets Fast-Track Designation in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 4:45PM CDT
Galmed Pharmaceuticals Ltd. (GLMD) announced that the FDA has granted fast track status to aramchol for the treatment of non-alcoholic steato-hepatitis.
Galmed Pharmaceuticals acquires US FDA's Fast Track Designation for Aramchol for NASH
M2 - Wed Sep 24, 6:24AM CDT
Biopharmaceutical company Galmed Pharmaceuticals (NasdaqCM :GLMD) reported on Tuesday the receipt of the US Food and Drug Administration's Fast Track Designation for aramchol for the treatment of Non-Alcoholic Steato-Hepatitis, or NASH.
Market Maker Surveillance Report. RITT, JRJC, UQM, GLMD, SINO, ECTE, Winning Stocks With Lowest Price Friction For Tuesday, September 23rd 2014
M2 - Wed Sep 24, 3:42AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4582 companies with "abnormal" market making, 1424 companies with positive Friction Factors and 3854 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Tuesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Rit Technologies Ltd (NASDAQ:RITT), China Finance Online Co Ltd (NASDAQ:JRJC), UQM Technologies Inc (NYSE:UQM), GOLD MEDAL RES LTD (NASDAQ:GLMD), Sino-Global Shipping America Ltd (NASDAQ:SINO), Echo Therapeutics Inc (NASDAQ:ECTE). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Why Galmed Pharmaceuticals (GLMD) Stock Is Surging Today
at The Street - Tue Sep 23, 2:50PM CDT
Shares of Galmed Pharmaceuticals (GLMD) soared Tuesday after the company announced the FDA had given Fast Track Designation to its drug candidate aramchol.
Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH
PR Newswire - Tue Sep 23, 9:47AM CDT
Galmed Pharmaceuticals Ltd. (Nasdaq:GLMD) ("Galmed"
Galmed Pharmaceuticals Completes Two Chronic Toxicology Studies and Reports No Significant Adverse Events
PR Newswire - Tue Sep 02, 7:00AM CDT
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"
Galmed Pharmaceuticals Reports First Half 2014 Financial Results
PR Newswire - Fri Jul 25, 7:00AM CDT
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (Galmed), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, today announced financial results for the period ended June 30, 2014.
Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders
PR Newswire - Tue Jul 22, 8:20AM CDT
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"
Galmed Pharmaceuticals Second Quarter 2014 Conference Call and Webcast Scheduled for Friday, July 25, 2014
PR Newswire - Mon Jul 21, 8:08AM CDT
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"
Galmed Announces Publication of Aramchol Phase IIa Trial in the Clinical Gastroenterology and Hepatology Journal
PR Newswire - Tue Jul 08, 9:33AM CDT
Galmed Pharmaceuticals Ltd. (Nasdaq:GLMD) ("Galmed"
Catalysts on the Horizon for Companies Developing NAFLD and NASH Drugs
ACCESSWIRE - Thu Jun 26, 8:41AM CDT
WHITEFISH, MT / June 26, 2014 / Those following the developments of Intercept Pharmaceuticals (NASDAQ: ICPT), Galectin Therapeutics (NASDAQ: GALT) and Galmed Pharmaceuticals (NASDAQ: GLMD) are keenly aware of the tendency of fatty liver disease drug developers to move in unity upon news of clinical research. The lack of viable treatments, increasing diagnosis rates and the economic burden associated with fatty livers has put a spotlight on the limited number of companies pursuing the indication, keeping investors on the lookout for news with market moving potential.
Leading Companies Being Defined in the Hunt for a NASH Treatment
ACCESSWIRE - Thu Mar 27, 9:32AM CDT
March 27, 2014 / The race to develop a treatment for Non-Alcoholic Steatohepatitis (NASH) is getting a lot of airtime lately, pointing to the severity of the disease, poor prognosis and desperate need for a treatment. The space has only a handful of competitors, with most seeing rising valuations due to the tremendous peak sales that analysts are projecting for products that make it to market. What is particularly unique to this disease is not only the lack of any approved treatments, but also the influx of attention and growing broad body of research by companies like Intercept Pharmaceuticals (NASDAQ: ICPT), Galmed Pharmaceuticals (NASDAQ: GLMD) and Galectin Therapeutics (NASDAQ: GALT) that shows treatments are on the horizon, which gives these equities considerable upside.
Galmed Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
PR Newswire - Tue Mar 18, 10:40AM CDT
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"
Galmed Pharmaceuticals Announces Pricing of Initial Public Offering
PR Newswire - Wed Mar 12, 7:07PM CDT
Galmed Pharmaceuticals Ltd. ("Galmed"